NATURE’S SUNSHINE PRODUCTS, INC. Research and Development Expense
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Research and Development Expense of $1.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-03-10
- NATURE’S SUNSHINE PRODUCTS, INC. research and development expense for fiscal 2025 was $1.90M, a 11.76% increase from fiscal 2024.
- NATURE’S SUNSHINE PRODUCTS, INC. research and development expense for fiscal 2024 was $1.70M, a 6.25% increase from fiscal 2023.
- NATURE’S SUNSHINE PRODUCTS, INC. research and development expense for fiscal 2023 was $1.60M, a 6.67% increase from fiscal 2022.
- NATURE’S SUNSHINE PRODUCTS, INC. research and development expense for fiscal 2022 was $1.50M, a 7.14% increase from fiscal 2021.
| Period end | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.90M 10-K · filed 2026-03-10 | |
| 2024-12-31 | $1.70M 10-K · filed 2026-03-10 | |
| 2023-12-31 | $1.60M 10-K · filed 2025-03-11 | |
| 2022-12-31 | $1.50M 10-K · filed 2024-03-12 | |
| 2021-12-31 | $1.40M 10-K · filed 2023-03-16 | |
| 2020-12-31 | $1.50M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $2.10M 10-K · filed 2021-03-10 | |
| 2018-12-31 | $2.80M 10-K · filed 2020-03-11 | |
| 2017-12-31 | $3.40M 10-K · filed 2019-03-08 | |
| 2016-12-31 | $3.20M 10-K · filed 2019-03-08 | |
| 2015-12-31 | $2.80M 10-K · filed 2018-03-16 | |
| 2014-12-31 | $2.50M 10-K · filed 2017-03-14 | $2.46M 10-K · filed 2015-03-13 |
| 2013-12-31 | $2.00M 10-K · filed 2016-03-14 | $2.04M 10-K · filed 2014-03-17 |
| 2012-12-31 | $1.46M 10-K · filed 2015-03-13 | |
| 2011-12-31 | $1.55M 10-K · filed 2014-03-17 | |
| 2010-12-31 | $2.02M 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |